Navigation Links
PharmAthene Reports Year-End 2012 Financial And Operational Results


19,795,84519,613,006Property and equipment, net

483,976788,666Other long-term assets and deferred costs


2,348,4532,348,453Total assets

$   22,741,404$   22,803,509LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

,445,700Accrued expenses and other liabilities

2,328,8772,655,330Deferred revenue

1,381,755514,312Current portion of long-term debt

749,997-Short-term debt

1,330,507-Total current liabilities

7,488,4164,615,342Other long-term liabilities

579,427449,709Long-term debt, less current portion

1,704,108-Derivative instruments

1,295,6131,886,652Total liabilities

11,067,5646,951,703Stockholders' equity:Common stock, $0.0001 par value; 100,000,000 shares authorized; 48,352,651 and 48,236,172 shares issued and outstanding at December 31, 2012 and 2011, respectively

4,8354,824Additional paid-in-capital

210,495,905208,525,917Accumulated other comprehensive (loss) income

(217,328)1,010,522Accumulated deficit

(198,609,572)(193,689,457)Total stockholders' equity

11,673,84015,851,806Total liabilities and stockholders' equity

$  22,741,404$  22,803,509 PHARMATHENE, INC.CONSOLIDATED STATEMENTS OF OPERATIONSYear Ended December 31,20122011Revenue

$ 25,175,887$  24,266,274Operating expenses:Research and development

19,509,62921,219,853General and administrative

11,628,73214,311,079Depreciation and amortization

303,916461,073Total operating expenses

31,442,27735,992,005Loss from operations

$ (6,266,390)$ (11,725,731)Other income (expense):Interest income

17,80816,660Interest expense

(342,561)(54,573)Gain on the sale of assets held for sale

-781,760Realization of cumulative translation adjustment 


SOURCE PharmAthene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
2. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
3. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
4. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
5. PharmAthene Reports First Quarter 2012 Financial Results
6. PharmAthene Reports Third Quarter 2012 Financial Results
7. PharmAthene To Present At The Noble Financial 9th Annual Equity Conference On Tuesday, January 22, 2013
8. PharmAthene To Host Year-End 2012 Conference Call And Webcast On Wednesday, March 13, 2013
9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
Post Your Comments:
(Date:8/27/2014)... 27, 2014 announces that a ... catalogue: Global Chelating Agents Market 2014-2018 ... About Chelating Agent A chelating agent is a ... metal ions, thereby forming a metal-ion complex. It ... on chemical processes, formulations, and the environment by ...
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 ... of Guggenheim Partners, today announced the hiring of veteran ... and senior equity analyst. Mr. Butler will focus on ... brings our team a wealth of experience and a ... Dante Ferrarie , Senior Managing Director and Head of ...
(Date:8/27/2014)... Aug. 27, 2014  ARCH Venture Partners, one ... in the development of seed and early-stage advanced ... fund closed with more than $400 million in ... million subscription target by more than $150 million. ... the strength and potential of our approach to ...
(Date:8/27/2014)... According to the 2013 Raw Material ... look and feel of markets for raw materials and ... will push for more branded, science-backed products.” , Natural ... market growth in the last decade as consumers increasingly ... cosmetics to fit a more ‘wellness’ lifestyle approach. ...
Breaking Biology Technology:Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3
... of Arpida Ltd (SWX: ARPN) has approved the proposals ... A total of 73 shareholders were present at the ... represented, or 29.3% of the total,number of shares issued ... 1. Approval of the 2007 Business Report, Company ...
... NeurogesX, Inc.,(Nasdaq: NGSX ), a biopharmaceutical company ... announced it will,report results for its first quarter 2008 ... A conference call to review the results will begin ... 2008 and will be hosted by Anthony DiTonno,President and ...
... cell company,Neuralstem, Inc. (Amex: CUR ) is filing ... StemCells intentionally withheld crucial,information highly material to the patentability ... this was done with the intent to deceive,the United ... patent allowed. As,a result of these actions, Neuralstem is ...
Cached Biology Technology:Arpida Annual General Meeting of Shareholders Approves All Board Proposals 2NeurogesX to Report First Quarter 2008 Financial Results 2NeurogesX to Report First Quarter 2008 Financial Results 3Neuralstem Sues StemCells, Inc. Over New Patent 2Neuralstem Sues StemCells, Inc. Over New Patent 3
(Date:8/27/2014)... group of fish began exploring land and evolved into tetrapods ... these ancient fish used their fishy bodies and fins in ... remain scientific mysteries. , Researchers at McGill University published ... fish, called Polypterus , to help show what might ... the water. Polypterus is an African fish that ...
(Date:8/27/2014)... is easier when it is related to ability that ... learn a new melody more easily than learning how ... the Center for the Neural Basis of Cognition (CNBC)a ... Mellon Universityhave discovered a fundamental constraint in the brain ... cover story in the Aug. 28, 2014, issue of ...
(Date:8/27/2014)... LAKE CITY, Aug. 27, 2014 University of Utah ... his native Turkey, has won that nation,s highest science ... of Science. , Sekercioglu is among five researchers picked ... and Technical Research Council of Turkey. Three researchers won ... won the Special Award, which is equivalent to the ...
Breaking Biology News(10 mins):Walking fish reveal how our ancestors evolved onto land 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 3University of Utah biologist wins Turkey's top science prize 2
... can aid forensics teams in determining if a person ... June issue of Radiology. , MDCT is comparable to ... are indicative of drowning. , "Our findings show ... reduce the need for conventional autopsy when drowning is ...
... H5N1 strain of avian influenza may hold the key to ... of researchers. In a study published today in the open ... antibodies taken from avian flu survivors in Vietnam can be ... virus in culture vitro and in mice. , The H5N1 ...
... researchers have uncovered the basis by which pregnant women ... the HIV virus works to counteract this defence. The ... in malaria-ravished regions. , Malaria is a parasitic disease ... people every year. While the disease affects mostly children, ...
Cached Biology News:'Virtual autopsy' helps identify drowning as cause of death 2Avian influenza survivors' antibodies effective at neutralising H5N1 strain 2HIV and malaria combine to adversely affect pregnant women and their infants 2
Mouse monoclonal antibody to ST8SIA2 - ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse monoclonal antibody raised against a partial recombinant RAB11B. NCBI Entrez Gene ID = RAB11B...
Biology Products: